Viral hepatitis guidelines in hemodialysis and transplantation.
D000998:Antiviral Agents / Q000627:therapeutic use; D006509:Hepatitis B / Q000453:epidemiology* / Q000517:prevention & control; D006526:Hepatitis C / Q000453:epidemiology* / Q000517:prevention & control / Q000635:transmission; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D016031:Liver Transplantation / Q000009:adverse effects*; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011183:Postoperative Complications / Q000453:epidemiology* / Q000821:virology; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects*; D012307:Risk Factors
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a